Abraxane Meets Primary Endpoint in Phase III Trial

March 17, 2010
Abraxis BioScience, Inc. Wednesday announced that its randomized registrational Phase 3 clinical trial comparing ABRAXANE (protein-bound paclitaxel) with Taxol (paclitaxel) injection, both in combination with carboplatin, met the study’s primary endpoint by demonstrating that ABRAXANE showed a significant improvement in overall response rate as compared to Taxol, in the first-line treatment of patients with advanced non-small cell lung cancer, as assessed by independent radiologist review.